Document:

FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT
​
THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “First Amendment”) is entered into as of August 20, 2021, by and between Sierra Bancorp, a California corporation (“Bancorp”), Bank of the Sierra, a California banking corporation (“Bank”), and Hugh Boyle (“Executive”) on the following terms and conditions.
​
WHEREAS, the Bank and Bancorp entered into an Employment Agreement with Executive (the “Agreement”) dated December 14, 2020; and
​
WHEREAS, Executive, the Bank and Bancorp have agreed to amend the Agreement to provide for certain revised terms in connection with Executive’s appointment as Chief Risk Officer;
​
NOW, THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Bank and Communities and the Executive hereto agree as follows:
​
1.Paragraph 1 of the Agreement is amended and restated in its entirety to read as follows:
​
Position.Executive shall be the Bank’s and Bancorp’s Executive Vice President, Chief Credit Officer (“CCO”) and Chief Risk Officer (“CRO”).  In that role, he shall have the duties set forth in this Agreement and in the By-Laws of the Bank and Bancorp, subject to the direction of the Chief Executive Officer (“CEO”) or the Board of Directors of the Bank or Bancorp, as applicable.  In addition to such other duties as may be assigned to him, Executive shall be a member of the Executive Officers’ Committee and shall perform such duties as are customarily performed by the CCO and CRO of a bank holding company and commercial bank.  
​
	2.	Effective August 20, 2021, Executive’s Base Salary as provided in Paragraph 8 of the Agreement shall be four hundred fourteen thousand dollars ($414,000).

​
	3.	Capitalized terms used herein and not otherwise defined shall have the same meaning as set forth in the Agreement.

​
	4.	This First Amendment may be entered into in one or more counterparts, all of which shall be considered one and the same instrument, and it shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties need not sign the same counterpart.

​

	5.	Except as expressly modified herein, the terms of the Agreement remain unchanged and in full force and effect.

​
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
​
EXECUTIVE
​
​
​ ​​ ​​ ​​ ​​ ​​ ​​
Hugh Boyle
​
​
SIERRA BANCORP
A California corporation
​
​
By:​ ​​ ​​ ​​ ​​ ​​ ​
Name:Kevin McPhaill
Title:President/CEO
​
​
​
BANK OF THE SIERRA 
A California banking corporation 
​
​
By:​ ​​ ​​ ​​ ​​ ​​ ​
Name:Kevin McPhaill
Title:President/CEO

2

​EX-4.8

 Exhibit 4.8 

Execution Version 

CA HEALTHCARE ACQUISITION CORP. 

AMENDMENT TO THE 
 AMENDED
AND RESTATED SPONSOR AGREEMENT 
 This AMENDMENT TO THE AMENDED AND RESTATED SPONSOR AGREEMENT (this “Amendment”) is
made as of August 19, 2021, by and among CA Healthcare Acquisition Corp., a Delaware corporation (“CAH”), CA Healthcare Sponsor LLC (the “Sponsor”) and each of the undersigned individuals, each of whom is a
member of CAH’s board of directors and/or management team (each, an “Insider” and collectively, the “Insiders”), in connection with that certain Amendment to the Agreement and Plan of Merger (the
“Merger Agreement”), dated as of the date hereof, by and among LumiraDx Limited, a Cayman Islands exempted company limited (the “Company”), LumiraDx Merger Sub, Inc., a Delaware corporation and a wholly-owned
subsidiary of the Company (“Merger Sub”), and CAH. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Merger Agreement. 

RECITALS 
 WHEREAS,
the Sponsor, CAH and the Insiders are parties to that certain Amended and Restated Sponsor Agreement dated as of April 6, 2021 (the “Sponsor Agreement”); 

WHEREAS, in connection with the amendment to the Merger Agreement, the Sponsor, CAH and the Insiders wish to amend certain provisions
of the Sponsor Agreement; 
 WHEREAS, Section 13 of the Sponsor Agreement provides that any term of the Sponsor Agreement may be
amended by a written instrument referencing the Sponsor Agreement and signed by (i) CAH, (ii) the Sponsor and (iii) the Insiders (collectively, the “Requisite Holders”) and (iv) the Company; 

WHEREAS, the undersigned parties to this written instrument constitute the Requisite Holders. 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: 

1. Amendments to the Sponsor Agreement. Clause (e) of Section 6 of the Sponsor Agreement is hereby deleted in its entirety and
replaced with the following: 
 “(e) Sponsor Equity Cancellation. 

  (i) In the event that more than fifty percent (50%) of the Class A Common Stock sold in the Public Offering is
redeemed, then an equal percentage of the Founder Shares shall be cancelled prior to giving effect to the CAH Class B Conversion (the “Forfeited Founder Shares”) and accordingly the Company shall have no obligation under this
Sponsor Agreement, the Merger Agreement or any other agreement relating to the Transactions to issue any Company Common Shares in respect of such Forfeited Founder 

 
Shares; provided however that for the period from the Closing Date and up to 31 December 2021 the Company, in its sole discretion, may elect to issue, on the same terms as provided for in
the Merger Agreement, Company Common Shares in respect of some or all of the Forfeited Founder Shares to the Sponsor. By way of illustrative example if 60% of the Class A Common Stock sold in the Public Offering is redeemed, then the Sponsor
shall only receive 1,150,000 Company Common Shares (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like). 

(ii) In the event that fifty percent (50%) or less of the Class A Common Stock sold in the Public Offering is redeemed,
then the Sponsor shall retain its entitlement to one hundred percent (100%) of its Founder Shares and its entitlement to Company Common Shares pursuant to the terms of the Merger Agreement (the “Entitlement”), subject to the
following vesting conditions for the Company Common Shares (the “Vesting Conditions”): (A) sixty percent (60%) of the Entitlement to Company Common Shares shall vest at Closing, (B) twenty percent (20%) of the
Entitlement to Company Common Shares shall vest if, at any time within eighteen (18) months of the Closing, the last reported closing price of the Company Common Shares equals or exceeds $12.50 per Company Common Share (as adjusted for share
splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading day period, and (C) twenty percent (20%) of the Entitlement to Company Common Shares shall vest if,
within thirty six (36) months of the Closing, the last reported closing price of the Company Common Shares equals or exceeds $15.00 per Company Common Share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and
the like) for any 20 trading days within any 30 consecutive trading day period. In the event that a Vesting Condition is not satisfied the relevant Entitlement to Company Common Shares shall lapse. ” 

2. Continued Validity of Sponsor Agreement. Except as specifically amended hereby, the Sponsor Agreement shall continue in full force
and effect as originally constituted and is ratified and affirmed by the parties hereto. 
 3. Successors and Assigns. Except as
otherwise provided herein, the terms and conditions of this Amendment shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. 

4. Governing Law. This Amendment shall be governed in all respects by the internal laws of the State of Delaware as applied to
agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law. 

5. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered by facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other
transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

  
 2 

 [Remainder of page intentionally left blank] 

  
 3 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above
written. 
  

			
	Sincerely,
	
	SPONSOR:
	
	CA HEALTHCARE SPONSOR LLC
		
	By:	 	 /s/ Tim McMahon

	Name: Tim McMahon
	Title: Managing Member
	
	INSIDERS:
		
	By:	 	 /s/ Larry J. Neiterman

	Name: Larry J. Neiterman
		
	By:	 	 /s/ Jeffrey H. Barnes

	Name: Jeffrey H. Barnes
		
	By:	 	 /s/ David Lang

	Name: David Lang
		
	By:	 	 /s/ David H. Klein

	Name: David H. Klein
		
	By:	 	 /s/ Afsaneh Naimollah

	Name: Afsaneh Naimollah

 [Signature Page to Amendment to the Amended and Restated Sponsor Agreement] 

			
	Acknowledged and Agreed:
	
	CA HEALTHCARE ACQUISITION CORP.
		
	By:	 	 /s/ Larry J. Neiterman

	Name: Larry J. Neiterman
	Title: Chief Executive Officer

 [Signature Page to Amendment to the Amended and Restated Sponsor Agreement] 

			
	Acknowledged and Agreed:
	
	LUMIRADX LIMITED
		
	By:	 	 /s/ Veronique Ameye

	Name: Veronique Ameye
	Title: Executive Vice President and General Counsel

 [Signature Page to Amendment to the Amended and Restated Sponsor Agreement]EX-4.21

 Exhibit 4.21 

Execution Version 

AMENDED AND RESTATED COMPANY HOLDERS SUPPORT AGREEMENT 

This Amended and Restated Company Holders Support Agreement (this “Agreement”) is dated as of
                    , 2021 by and between LumiraDx Limited, a Cayman Islands exempted company limited by shares with company number 314391 (the
“Company”) and each of the security holders of the Company whose names appear on the signature pages of this Agreement (each, a “Holder” and collectively, the “Holders”). Capitalized terms used but
not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). 
 RECITALS

 WHEREAS, as of the date hereof each Holder is the holder of record and the “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange Act) of the number of Company Ordinary Shares, Company Series A Preferred Shares, Company Series B Preferred Shares, Company Common Shares, 2020 Warrants, 5% Convertible Loan Notes or 10%
Convertible Loan Notes (collectively, “Securities”) as set forth on Schedule I attached hereto (collectively, with respect to each Holder, such Holder’s “Owned Securities,” and such Owned Securities,
together with (1) any additional Securities in which such Holder acquires record and beneficial ownership after the date hereof, including (i) by exercise or exchange of securities convertible or exercisable into Securities, (ii) by
purchase, (iii) as a result of a dividend, split, recapitalization, combination, reclassification, exchange or change of such securities issued by the Company or (iv) upon exercise or conversion of any securities and (2) any
additional Securities with respect to which such Holder has the right to vote through a proxy, the “Covered Securities”); 

WHEREAS, on April 6, 2021 the Company, LumiraDx Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and CA
Healthcare Acquisition Corp., a Delaware Corporation (“SPAC”) entered into an Agreement and Plan of Merger (the “Original Merger Agreement); 

WHEREAS, on or around the date of this Agreement, the Company, Merger Sub and SPAC have entered into an amendment (the “Merger
Agreement Amendment”) to the Original Merger Agreement, which reduces the Company Valuation from $5.0 billion to $3.0 billion (the Original Merger Agreement, as amended by the Merger Agreement Amendment, being the “Merger
Agreement” for the purposes of this Agreement). 
 WHEREAS, pursuant to the Merger Agreement, among other transactions, Merger Sub
will be merged with and into SPAC, with SPAC continuing as the surviving entity and a wholly-owned subsidiary of the Company, on the terms and conditions set forth therein (the “Merger”); and 

WHEREAS, this Agreement shall amend and restate the company holders support agreement dated April 6, 2021 (the “Original Support
Agreement”), which the Holders were required to deliver concurrently with the execution and delivery of the Original Merger Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby, the
parties hereto hereby agree as follows: 

 ARTICLE I 

COMPANY HOLDERS SUPPORT; COVENANTS 

1.01 Support of Company Holders.  

(a) Each Holder, solely in his, her or its capacity as a holder of Securities or proxy holder of Securities, agrees irrevocably and
unconditionally, that at any Company Meeting, however called, or at any adjournment or postponement thereof, or in any other circumstance in which the vote, consent or other approval of the Holders of Securities is sought, such Holder shall
(i) appear at each such meeting in person or by proxy or otherwise cause all of its Covered Securities to be counted as present thereat for purposes of calculating a quorum and (ii) vote or provide consent (or cause to be voted or
consented), in person or by proxy, or execute and deliver a written consent (or cause a written consent to be executed and delivered) covering, all of its Covered Securities owned as of the record date for such meeting (or the date that any written
consent is executed by such Holder): 
 (i) in favor of each Company Proposal that such Holder is entitled to vote on as the holder of any
class, series or type of Covered Securities; 
 (ii) against any merger agreement, merger, exchange, consolidation, combination, sale of
substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company or any other business combination proposal (other than the Merger Agreement and the transactions contemplated thereby); and 

(iii) against any proposal, action or agreement that would reasonably be expected to (A) impede, nullify, frustrate, prevent, interfere
with, materially delay the consummation of, or otherwise adversely affect, any of the transactions contemplated by the Merger Agreement, any Ancillary Agreement, the Merger or any provision of this Agreement, (B) result in a breach in any
respect of any covenant, representation, warranty or any other obligation or agreement of the Company under the Merger Agreement or any Ancillary Agreement, or (C) result in any of the conditions set forth in Article VII of the Merger Agreement
not being fulfilled. 
 (b) Each Holder hereby covenants and agrees that such Holder shall not (i) enter into any voting agreement or
voting trust with respect to any of such Holder’s Covered Securities that is inconsistent with such Holder’s obligations pursuant to this Agreement, (ii) grant a proxy or power of attorney with respect to any of such Holder’s
Covered Securities that is inconsistent with such Holder’s obligations pursuant to this Agreement, or (iii) enter into any agreement or undertaking that is otherwise inconsistent with, or would restrict, limit or interfere with, or
prohibit or prevent it from satisfying, its obligations pursuant to this Agreement. 
 1.02 No Transfer. During the period commencing
on the date hereof and ending on the earlier of (a) the Effective Time and (b) such date and time as the Merger Agreement shall be terminated in accordance with Section 8.1 (Termination) thereof, each
Holder shall not, except in each case pursuant to or as contemplated by the Merger Agreement, (i) directly or indirectly, sell (including short sells), offer to sell, contract or agree to sell, hypothecate, pledge, encumber, grant any Lien or
option to purchase or otherwise dispose of or enter into an agreement to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidation with respect to or decrease a call equivalent position within the meaning
of Section 16 of the Exchange Act, and the rules and regulations of the Commission promulgated 

 
thereunder with respect to any Covered Securities owned by such Holder, either voluntarily or involuntarily, (ii) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of any Covered Securities owned by such Holder, whether any such transaction is to be settled by delivery of such Covered Securities, in cash or otherwise or (iii) publicly announce any
intention to effect any transaction specified in clause (i) or (ii) (collectively, a “Transfer”); or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any
profit-sharing arrangement) with respect to, or consent to, a Transfer of, any or all of the Covered Securities, provided, however, that the foregoing shall not prohibit either (A) the conversion or exchange of securities convertible into or
exchangeable for Securities in accordance with their terms or (B) Transfers between such Holder and any Affiliate of such Holder or to another Holder of the Company that is a party to this Agreement and bound by the terms and obligations hereof
or agrees to become a party to this Agreement and signs a joinder hereto in form and substance satisfactory to the Company. Each Holder hereby authorizes the Company to maintain a copy of this Agreement at either the executive office or the
registered office of the Company. 
 1.03 Further Assurances. Each Holder agrees that Section 6.9 (Public Announcements)
of the Merger Agreement shall apply to such Holder mutatis mutandis and such Holder shall agree to be bound by the same as if such Holder were a party to the Merger Agreement. 

1.04 Disclosure. Such Holder hereby authorizes the Company and SPAC to publish and disclose in any announcement or disclosure required
by the SEC such Holder’s identity and ownership of the Covered Securities and the nature of such Holder’s obligations under this Agreement, to the extent necessary to comply with applicable Law. 

ARTICLE II 

REPRESENTATIONS AND WARRANTIES 

2.01 Representations and Warranties of each Holder. Each Holder represents and warrants, severally (and not jointly and severally) as
to itself only, as of the date hereof to the Company as follows: 
 (a) Organization; Due Authorization. (i) if such Holder is a
natural person, such person has all the requisite power and authority and has taken all action necessary in order to execute and deliver this Agreement, to perform his or her obligations hereunder, and (ii) is duly organized, validly existing
and in good standing under the laws of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are
within such person’s corporate, limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such person. This Agreement has been
duly executed and delivered by each Holder and, assuming due authorization, execution and delivery by the other parties to this Agreement, this Agreement constitutes a legally valid and binding obligation of each Holder, enforceable against each
Holder in accordance with the terms hereof (except as enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and general principles of
equity). If this Agreement is being executed in a representative or fiduciary capacity, the person signing this Agreement has full power and authority to enter into this Agreement on behalf of said Holder. 

 (b) Ownership. Each Holder is the record, legal and beneficial owner (as defined in
the Securities Act) of, and has good title to, all of such Holder’s Covered Securities listed on Schedule I hereto, and there exist no Liens or any other limitation or restriction (including any restriction on the right to vote, sell or
otherwise dispose of such Covered Securities (other than transfer restrictions under the Securities Act)) affecting any such Covered Securities, other than Liens pursuant to (i) this Agreement, (ii) if applicable, the Holder’s
organizational documents, (iii) the Merger Agreement, or (iv) any applicable securities Laws. The execution, delivery and performance of this Agreement by each Holder does not, and the consummation of the transactions contemplated hereby
and the other transactions contemplated by the Merger Agreement will not, constitute or result in, with or without notice, lapse of time or both, a breach or violation of, a termination (or right of termination) of or a default under, the loss of
any benefit under, the creation, modification or acceleration of any obligations under or the creation of a Lien on any of the properties, rights or assets of each Holder pursuant to any Contracts binding upon any Holder or under any applicable Law
to which each Holder is subject. Each Holder’s Covered Securities are the only Securities in the Company owned of record or beneficially by such Holder on the date of this Agreement, and none of such Holder’s Covered Securities are subject
to any proxy, voting trust or other agreement or arrangement with respect to the voting of such Covered Securities, except as provided hereunder. 

(c) No Conflicts. The execution and delivery of this Agreement by each Holder does not, and the performance by each Holder of its
obligations hereunder and other transactions contemplated by the Merger Agreement will not, (i) conflict with or result in a violation of the organizational documents of such Holder that is not a natural person or (ii) require any consent
or approval that has not been given or other action that has not been taken by any person (including under any Contract binding upon such Holder or such Holder’s Covered Securities), in each case, to the extent such consent, approval or other
action would prevent, enjoin or materially delay the performance by such Holder of its, his or her obligations under this Agreement. 
 (d)
Litigation. There is no action, proceeding or investigation pending against any Holder or, to the knowledge of any Holder, threatened against any Holder that questions the beneficial or record ownership of the Holder’s Owned Securities,
the validity of this Agreement or which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by each Holder of its, his or her obligations under this Agreement. 

(e) Acknowledgment. Each Holder understands and acknowledges that each of SPAC and the Company is entering into the Merger Agreement in
reliance upon such Holder’s execution and delivery of this Agreement. 
 (f) Each Holder has had adequate information concerning the
business and financial condition of the Company and the Merger to make an informed decision regarding this Agreement and has independently and without reliance upon the company or SPAC and based on such information as each Holder has deemed
appropriate, made its own analysis and decision to enter into this Agreement. The Holder acknowledges that the Company and SPAC have not made and do not make any representation or warranty, whether express or implied, of any kind or character except
as expressly set forth in this Agreement. 

 ARTICLE III 

MISCELLANEOUS 

3.01 Termination. This Agreement and all of its provisions shall terminate and be of no further force or effect upon the earlier of
(a) the termination of the Merger Agreement in accordance with its terms, (b) the Effective Time and (c) the written agreement of each Holder and the Company. Upon such termination of this Agreement, all obligations of the parties
under this Agreement will terminate, without any liability or other obligation on the part of any party hereto to any person in respect hereof or the transactions contemplated hereby, and no party hereto shall have any claim against another (and no
person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; provided, however, that the termination of this Agreement shall not relieve any party hereto from liability
arising in respect of any willful breach of this Agreement prior to such termination. This ARTICLE III shall survive the termination of this Agreement. 

3.02 Governing Law; Jurisdiction; Waiver of Jury Trial. Sections 9.6 (Governing Law) and 9.7 (Waiver of Jury
Trial) of the Merger Agreement are incorporated herein by reference, mutatis mutandis. 
 3.03 Entire Agreement; Assignment;
Third Party Beneficiaries. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties, or any of
them, with respect to the subject matter hereof. This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise) by any party without the prior express written consent of the other parties hereto. SPAC is
expressly made a third party beneficiary of this Agreement and shall be entitled to enforce this Agreement in the same manner as if SPAC were a party hereto. 

3.04 Specific Performance. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed
in accordance with the terms hereof, and, accordingly, that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in the
Court of Chancery of the State of Delaware or, if that court does not have jurisdiction, any court of the United States located in the State of Delaware or, if that court does not have jurisdiction, any other court of the United States, the United
Kingdom or any other jurisdiction that has jurisdiction over the relevant Holder or Holders, without proof of actual damages or otherwise, in addition to any other remedy to which they are entitled at law or in equity as expressly permitted in this
Agreement. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any Law to post security or a bond as a prerequisite to
obtaining equitable relief. 
 3.05 Amendment. This Agreement may not be amended, changed, supplemented, waived or otherwise modified
or terminated, except upon the execution and delivery of a written agreement executed by the Company and the Holder or Holders affected thereby, it being agreed that the Company shall not consent to any amendment, change, waiver, modification or
termination of this Agreement without the prior written consent of SPAC. 
 3.06 Severability. If any provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the
Merger and the transactions contemplated thereby shall be consummated as originally contemplated to the fullest extent possible. 

 3.07 Notices. All notices and other communications among the parties hereto shall be
in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid,
(c) when delivered by FedEx or other nationally recognized overnight delivery service or (d) when e-mailed during normal business hours (and otherwise as of the immediately following Business Day),
addressed as follows: 
 If to the Company to: 

3 More London Riverside 
 London
SE1 2AQ 
 United Kingdom 

Email: Veronique.ameye@lumiradx.com 

with a copy to: 
 Fried, Frank,
Harris, Shriver & Jacobson LLP 
 One New York Plaza 

New York, NY 10004 
 Attention:
Warren S. de Wied 
 Email: warren.de.wied@friedfrnak.com 

and to: 
 Fried, Frank, Harris,
Shriver & Jacobson (London) LLP 
 100 Bishopsgate, London, EC2N 4AG 

United Kingdom 
 Attention: Ian
Lopez 
 Email: ian.lopez@friedfrank.com 

and to: 
 Goodwin Procter LLP 

100 Northern Avenue 
 Boston, MA
02210 
 Attention: Edwin O’Connor; Paul R. Rosie 

Email: eoconnor@goodwinlaw.com; prosie@goodwinlaw.com 

If to any Holder, to the address or email address set forth opposite such Holder’s name on Schedule I, or in the absence of such
address or email address being set forth on Schedule I, the address (including email) set forth in the Company’s books and records. 

 3.08 Counterparts; Electronic Delivery. This Agreement may be executed in
counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same instrument. The words “execution,” “signed,” “signature,” and
words of like import in this Agreement shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, “pdf”, “tif” or “jpg”) and other electronic
signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored
by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic
Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform
Commercial Code. 
 3.09 Capacity as a Holder. Notwithstanding anything herein to the contrary, each Holder signs this Agreement
solely in the Holder’s capacity as a Holder or proxy holder of Securities, and not in any other capacity and this Agreement shall not limit, prevent or otherwise affect the actions of such Holder or any Affiliate, employee or designee of such
Holder or any of their respective Affiliates in his or her capacity, if applicable, as an officer or director of the Company (or any Subsidiary of the Company) or any other person, including in the exercise of his or her fiduciary duties as a
director or officer of the Company or any Subsidiary of the Company. No Holder shall be liable or responsible for any breach, default, or violation of any representation, warranty, covenant or agreement by any other Holder that is also a party
hereto and each Holder shall solely be required to perform its obligations hereunder in its individual capacity. 
 [THE REMAINDER OF THIS
PAGE IS INTENTIONALLY BLANK] 

 IN WITNESS WHEREOF, the Company and the Holders have each caused this Agreement to be duly
executed as of the date first written above. 
  

			
	LUMIRADX LIMITED
		
	By:	 	 /s/ Veronique Ameye

	Name: Veronique Ameye
	Title: Executive Vice President and General Counsel

 
			
	HOLDER:
	
	Zwanziger Family Ventures LLC
		
	By:	 	 /s/ Ron Zwanziger

	Name: Ron Zwanziger
	
	Zwanziger Ventures, LLC
		
	By:	 	 /s/ Ron Zwanziger

	Name: Ron Zwanziger
	
	Treisar Investments Limited
		
	By:	 	 /s/ Ron Zwanziger

	Name: Ron Zwanziger
	
	Ron Zwanziger
	 /s/ Ron Zwanziger

	
	David Scott
	  

	
	Jerome McAleer
	  

	
	Willard L. Umphrey
	  

	
	Anne Umphrey
	  

 
			
	 Pensco Trust Company Custodian FBO

Willard L Umphrey Roth IRA, Tax ID #02-0526633

		
	By:	 	             

	Name: Willard L. Umphrey
	
	USB Focus Fund LumiraDx 1-A, LLC
		
	By:	 	  

	Name: John McAleer
	Title: Managing Member, Pear Tree Partners
	
	USB Focus Fund LumiraDx 1-B, LLC
		
	By:	 	  

	Name: John McAleer
	Title: Managing Member, Pear Tree Partners
	
	For and on behalf of Morningside Venture Investments Limited
		
	By:	 	  

	Name: Jill Marie Franklin
	Title: Authorized Signatory
		
	By:	 	  

	Name: Frances Anne Elizabeth Richard
	Title: Authorized Signatory
	
	For and on behalf of MVIL, LLC
		
	By:	 	  

	Name: Cheng Yee Wing Betty
	Title: Authorized Signatory
		
	By:	 	  

	Name: Wong See Wai
	Title: Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]